Help advance the understanding and treatment of brain tumors.
The FDA Wants 23andMe To Stop Marketing Its Genetic Testing Kits
The FDA is ordering 23andMe to stop marketing its saliva collection kits for its personal genome service.
Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagen's Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
Additional Preclinical Studies Demonstrate Potential for Intravenous Administration of Toca 511 and Use in Combination with Temozolomide and Radiation
Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone
biOasis Technologies Inc., a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research
Study Finds Potential Treatment for Deadly Brain Cancer
Research findings from Northwestern University Feinberg School of Medicine.
University of Queensland's Institute for Molecular Bioscience Study Finds 50 Genes Linked to Type of Childhood Brain Tumor
Findings from a research study on medulloblastoma.
Study Opens Doors to Novel Treatments for Aggressive Brain Cancer
Research from the Ludwig Institute for Cancer Research.
Bexion Pharmaceuticals Awarded $2.9MM SBIR Bridge Award by National Cancer Institute to Support Phase I First-in-Human Clinical Trial in Cancer
Bexion Pharmaceuticals has been awarded a Small Business Innovation Research (SBIR) "Bridge Award" by the National Cancer Institute (NCI).
Drug Preserves Cognitive Function After Whole Brain Radiotherapy for Brain Cancer
Research from Emory's Nell Hodgson Woodruff School of Nursing and the Winship Cancer Institute.
Trial Combining Anti-Cancer Drug and Radiotherapy May Lead to Treatment for BrainTumor
Research presented at the 2013 European Cancer Congress
New Approach to Treating Human Brain Cancer Could Lead to Improved Outcomes
Research from Sanford-Burnham's NCI-Designated Cancer Center, led by Robert, Wechsler-Reya, PhD, and ABTA Scientific Advisory Council member.